Herjan J.T. Coelingh Bennink
MD, PhD, trained in Gynaecology and Internal medicine in Leiden and in Utrecht, The Netherlands and certified in 1976 as specialist in ObGyn. Since 1976 he was director of the Department of Reproductive Endocrinology at the University Hospital in Utrecht. In 1987 he joined Organon in The Netherlands as Executive VP of the Women’s Health R&D programme and developed drugs such as Puregon and Antagon for IVF, the Nuvaring, the Implanon and Cerazette for contraception and Livial (tibolone) for HRT. From 1997-2005 he was professor WH at the Dutch speaking Free University in Brussels, Belgium. He founded Pantarhei Bioscience (PRB) in 2001. In 2014 he founded Pantarhei Oncology (PRO) for the development of drugs for reproductive tract cancers.